Recent Finacing
Recent Raise
Avilar Therapeutics develops ATACs—ASGPR-targeting chimeras that bind extracellular proteins and shuttle them to hepatocyte endolysosomes for degradation, using a modular ASGPR-ligand discovery platform and proteome-mapping informatics.
